ORBIMED ADVISORS LLC - 02 Nov 2026 Form 4 Insider Report for Aspen Neuroscience, Inc. (ASPE)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: ASPE
Reported as of: 02 Nov 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Nov 2026, 18:43:12 UTC
Prior SEC filing: 29 Oct 2026
Next SEC filing: 05 Nov 2026
Source filing: View source filing
Reporting owner signature: /s/ Carl L. Gordon, Member of OrbiMed Advisors LLC

Filing notes and source

Key filing fact

ORBIMED ADVISORS LLC filed Form 4 for Aspen Neuroscience, Inc. (ASPE) on 04 Nov 2026.

Key facts

This page summarizes ORBIMED ADVISORS LLC's Form 4 filing for Aspen Neuroscience, Inc. (ASPE).
11 reported transactions and 10 derivative rows are listed below.
Accepted by SEC: 04 Nov 2026, 18:43.

Change

Previous filing in this sequence was filed on 29 Oct 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (2)

CIK 0001055951 Primary reporting owner

ORBIMED ADVISORS LLC

Relationship: Director, 10%+ Owner
Address: 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK
Signature: /s/ Carl L. Gordon, Member of OrbiMed Advisors LLC
Signature date: 04 Nov 2026

CIK 0001760648

OrbiMed Capital GP VII LLC

Relationship: Director, 10%+ Owner
Address: 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK
Signature: /s/ Carl L. Gordon, Member of OrbiMed Capital GP VII LLC
Signature date: 04 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ASPE transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +196,541
Change %
Price
Shares after: 196,541
Date: 02 Nov 2026
Ownership: See footnotes
Footnotes: F1, F3, F4

ASPE transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +196,541
Change %
Price
Shares after: 196,541
Date: 02 Nov 2026
Ownership: See footnotes
Footnotes: F1, F3, F4

ASPE transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +642,745
Change %: +327%
Price
Shares after: 839,286
Date: 02 Nov 2026
Ownership: See footnotes
Footnotes: F1, F3, F4

ASPE transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +642,745
Change %: +327%
Price
Shares after: 839,286
Date: 02 Nov 2026
Ownership: See footnotes
Footnotes: F1, F3, F4

ASPE transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +616,984
Change %: +74%
Price
Shares after: 1,456,270
Date: 02 Nov 2026
Ownership: See footnotes
Footnotes: F1, F3, F4

ASPE transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +616,984
Change %: +74%
Price
Shares after: 1,456,270
Date: 02 Nov 2026
Ownership: See footnotes
Footnotes: F1, F3, F4

ASPE transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +625,743
Change %: +43%
Price
Shares after: 2,082,013
Date: 02 Nov 2026
Ownership: See footnotes
Footnotes: F1, F3, F4

ASPE transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +625,743
Change %: +43%
Price
Shares after: 2,082,013
Date: 02 Nov 2026
Ownership: See footnotes
Footnotes: F1, F3, F4

ASPE transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +507,119
Change %: +24%
Price
Shares after: 2,589,132
Date: 02 Nov 2026
Ownership: See footnotes
Footnotes: F1, F3, F4

ASPE transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +507,119
Change %: +24%
Price
Shares after: 2,589,132
Date: 02 Nov 2026
Ownership: See footnotes
Footnotes: F1, F3, F4

ASPE transaction

Common Stock

Purchase

Transaction value
Shares: +1,000,000
Change %: +39%
Price: $15.00^*
Shares after: 3,589,132
Date: 02 Nov 2026
Ownership: See footnotes
Footnotes: F2, F3, F4

ASPE transaction

Common Stock

Purchase

Transaction value
Shares: +1,000,000
Change %: +39%
Price: $15.00^*
Shares after: 3,589,132
Date: 02 Nov 2026
Ownership: See footnotes
Footnotes: F2, F3, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ASPE transaction Derivative

Series Seed-2 Convertible Preferred Stock

Conversion of derivative security

Transaction value
Shares: -196,541
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Nov 2026
Ownership: See footnotes
Underlying class: Common Stock
Underlying amount: 196,541
Exercise price
Footnotes: F1, F3, F4

ASPE transaction Derivative

Series Seed-2 Convertible Preferred Stock

Conversion of derivative security

Transaction value
Shares: -196,541
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Nov 2026
Ownership: See footnotes
Underlying class: Common Stock
Underlying amount: 196,541
Exercise price
Footnotes: F1, F3, F4

ASPE transaction Derivative

Series A-1 Convertible Preferred Stock

Conversion of derivative security

Transaction value
Shares: -642,745
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Nov 2026
Ownership: See footnotes
Underlying class: Common Stock
Underlying amount: 642,745
Exercise price
Footnotes: F1, F3, F4

ASPE transaction Derivative

Series A-1 Convertible Preferred Stock

Conversion of derivative security

Transaction value
Shares: -642,745
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Nov 2026
Ownership: See footnotes
Underlying class: Common Stock
Underlying amount: 642,745
Exercise price
Footnotes: F1, F3, F4

ASPE transaction Derivative

Series A-2 Convertible Preferred Stock

Conversion of derivative security

Transaction value
Shares: -616,984
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Nov 2026
Ownership: See footnotes
Underlying class: Common Stock
Underlying amount: 616,984
Exercise price
Footnotes: F1, F3, F4

ASPE transaction Derivative

Series A-2 Convertible Preferred Stock

Conversion of derivative security

Transaction value
Shares: -616,984
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Nov 2026
Ownership: See footnotes
Underlying class: Common Stock
Underlying amount: 616,984
Exercise price
Footnotes: F1, F3, F4

ASPE transaction Derivative

Series B Convertible Preferred Stock

Conversion of derivative security

Transaction value
Shares: -625,743
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Nov 2026
Ownership: See footnotes
Underlying class: Common Stock
Underlying amount: 625,743
Exercise price
Footnotes: F1, F3, F4

ASPE transaction Derivative

Series B Convertible Preferred Stock

Conversion of derivative security

Transaction value
Shares: -625,743
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Nov 2026
Ownership: See footnotes
Underlying class: Common Stock
Underlying amount: 625,743
Exercise price
Footnotes: F1, F3, F4

ASPE transaction Derivative

Series C Convertible Preferred Stock

Conversion of derivative security

Transaction value
Shares: -507,119
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Nov 2026
Ownership: See footnotes
Underlying class: Common Stock
Underlying amount: 507,119
Exercise price
Footnotes: F1, F3, F4

ASPE transaction Derivative

Series C Convertible Preferred Stock

Conversion of derivative security

Transaction value
Shares: -507,119
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Nov 2026
Ownership: See footnotes
Underlying class: Common Stock
Underlying amount: 507,119
Exercise price
Footnotes: F1, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Pursuant to the Issuer's Amended and Restated Certificate of Incorporation, as amended, each share of Series Seed-2 Convertible Preferred Stock, Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock, and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible, at the option of the holder, at any time. In connection with the completion of the Issuer's initial public offering of its Common Stock, each share of Preferred Stock automatically converted on a 1-for-9.8821 basis into shares of Common Stock, for no additional consideration. Share numbers give effect to such conversion. The securities have no expiration date.

Footnote F2

Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering.

Footnote F3

Securities held by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("OrbiMed GP") is the general partner of OPI VII. OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of OrbiMed GP. By virtue of such relationships, OrbiMed GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VII. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VII, except to the extent of its or his pecuniary interest therein if any.

Footnote F4

This report on Form 4 is jointly filed by OrbiMed Advisors and OrbiMed GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Peter Thompson, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.